期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 75, 期 2, 页码 115-120出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2012.11.009
关键词
Enterobacteriaceae; Carbapenem resistance; Multidrug resistance; Mortality; Bacteremia
资金
- Clinical and Translational Science Collaborative of Cleveland
- National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1TR000439]
- NIH roadmap for Medical Research
- Public Health Service grants from the National Institutes of Health [R01AI072219, R01AI063517]
- Cleveland Department of Veterans Affairs
- Veterans Affairs Merit Review Program
- Geriatric Research Education and Clinical Center [VISN 10]
- Research Program Committees of the Cleveland Clinic
- STERIS Corporation
- National Institute of Allergy and Infectious Diseases (NIAID)
- DMID [10-0065]
The emergence of carbapenem resistance in Enterobacteriaceae is an important threat to global health. Reported outcomes of infections with carbapenem-resistant Enterobacteriaceae (CRE) are poor. Very few options remain for the treatment of these virulent organisms. Antibiotics which are currently in use to treat CRE infections include aminoglycosides, polymyxins, tigecycline, fosfomycin, and temocillin. In addition, the role of combination therapy, including carbapenem containing regimens, remains to be defined. There are several important concerns regarding all of these treatment options such as limited efficacy, increasing reports of resistance, and specific toxicities. Data from retrospective studies favor combination therapy over single-agent therapy for the treatment of CRE bloodstream infections. In summary, new antibiotics are greatly needed, as is additional prospective research. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据